BMY Declares $0.60 Dividend, Extends 95-Year Streak

Bristol-Myers Squibb Company (NYSE:BMY) is the third biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 17, the company announced a quarterly cash dividend of $0.60 per share on its common stock. This is the 95th consecutive year that the conglomerate has paid a dividend.

BMY Declares $0.60 Dividend, Extends 95-Year Streak

The latest dividend is payable on August 1, 2025, a slight decline (by $0.02) compared to the previous payment in February this year. However, the payment is higher than the $0.57 per share for all four payments in 2023. In 2024, the company started the payment with a $0.60 per share dividend (5.26% higher than 2023) on February 1, which was maintained for all four payments of the year.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical firm. It discovers, develops, and markets prescription medicines for serious diseases in areas like oncology, hematology, immunology, cardiovascular, and neuroscience. Its leading products include Opdivo, Eliquis, Revlimid, Yervoy, and Sotyktu.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Biotech Stocks Screaming a Buy and 13 Best Software Stocks to Buy Now.

Disclosure: None.